Musk's Neuralink Wins FDA Approval for Brain Implant Research

Elon Musk’s Neuralink Granted FDA Approval for Human Brain Implant Research

/ 01:12 AM May 26, 2023

Neuralink, the brain-implant company owned by billionaire Elon Musk, has achieved a significant milestone in its goal to push the limits of human potential.

On Thursday, the US Food and Drug Administration (FDA) approved Neuralink’s first human clinical tests. This marks a significant breakthrough after difficulties in securing FDA approval.

Tech mogul Elon Musk has a bold vision for Neuralink’s future technology. He believes that it could possibly cure conditions such as autism, obesity, schizophrenia, and depression.

What is Neuralink?

Founded in 2016, this ultramodern neurotechnology company aims to develop brain-machine interface (BMI) implants. These devices will enable direct communication between computers and the human brain.

As it can potentially cure various medical conditions, it is designed to cure neurological disorders and even improve cognition. Despite earning public scrutiny and regulatory challenges, it is still at the top of biology, neuroscience, and technological advancements.

You may also like: No More Typing: Scientists Create Brain Implant for Social Media Navigation

In a technology-dependent world, these implants may even facilitate telepathy and web browsing. Musk’s trust in the safety of these devices is so high that he stated he was willing to have his own children implanted too.

Overcoming Regulatory Issues

However, gaining FDA approval has not been an easy journey. In 2019, Elon Musk expected on four different events that Neuaralink could start human trials.

In 2022, Neuralink first applied for FDA approval but was rejected. According to Reuters, seven former and current employees confirmed this in March 2023.

The FDA noted several concerns about Neuralink that they must acknowledge before giving the green light to human trials. Some of these concerns are the implant wires’ risks of moving inside the brain, the device’s lithium battery, and the safety of the device removal without harming the brain tissue.

Neuralink also faced public criticism, and the neurotechnology company has been under federal probes.

In May 2023, US lawmakers asked the regulators to investigate the panel supervising animal trials at Neuralink. This is after accusations of botched and rushed experiments surfaced.

The US Department of Agriculture’s Office of the Inspector General is also investigating possible animal-welfare negligence.

In addition, the Department of Technology is probing if Neuralink has illegally transported hazardous pathogens on chips they have removed from monkey brains without appropriate containment securities.

Neuralink’s Next Steps

Despite the hurdles, the company kept its top momentum. FDA’s approval is the first critical step that could open the doors to the widespread trials of this advanced technology.

You may also like: Elon Musk Faces Subpoena in Virgin Islands’ Epstein Lawsuit Against JPMorgan

Neuralink tweeted, “This represents an important first step that will one day allow our technology to help many people.”

Still, as Neuralink moves to its next steps, the details of the study are still unknown. The company will soon begin recruitment for the trial and announce to release details soon.

If successful, these devices can transform the norm of treating various diseases. Amid the challenges, one thing is for sure; Neuralink’s story is just getting started.

For more updates on the latest news and interesting articles, stay tuned at

Don't miss out on the latest news and information.
TAGS: Elon Musk, Trending, US FDA
For feedback, complaints, or inquiries, contact us.
Your subscription could not be saved. Please try again.
Your subscription has been successful.

Subscribe to our daily newsletter

By providing an email address. I agree to the Terms of Use and acknowledge that I have read the Privacy Policy.

We use cookies to ensure you get the best experience on our website. By continuing, you are agreeing to our use of cookies. To find out more, please click this link.